. 2019 Jun 6;97(8):548–562P. doi: 10.2471/BLT.18.228486

Table 2. Included studies on chlamydia, gonorrhoea and trichomoniasis prevalence in men, 2009–2016.

Study, by WHO region	Country or territory and location	Date of study	Population and age, years	Chlamydia			Gonorrhoea			Trichomoniasis
Study, by WHO region	Country or territory and location	Date of study	Population and age, years	Clinical specimen, test^a	Sample size	Study prevalence, %	Clinical specimen, test^a	Sample size	Study prevalence, %	Clinical specimen, test^a	Sample size	Study prevalence, %
African Region
Francis et al., 2018⁴²	South Africa, KwaZulu-Natal	Oct 2016–Jan 2017	Community members, 15–24	Urine, amplification test	188	5.3	Urine, amplification test	188	1.6	Urine, amplification test	188	0.5
Rutherford et al., 2014⁴⁶	Uganda, Kampala	Sep 2008–Apr 2009	Students, 19–25	Urine, amplification test	360	0.8	Urine, amplification test	360	0.0	NR	NR	NR
de Walque et al., 2012⁴⁷	United Republic of Tanzania, Kilombero and Ulanga districts	Feb–April 2009	Participants in HIV prevention trial, 18–30	Urine, amplification test	1195	1.7	Urine: amplification test	1195	0.4	Urine, amplification test	1195	8.5
Region of the Americas
Huneeus et al., 2018⁷²	Chile, Santiago	2012–2014	Sexually active students, ≤ 24	Urine, amplification test	115	8.7	Urine, amplification test	115	0.0	Urine, amplification test	115	0.0
Paredes et al., 2015⁷⁵	Colombia, Sabana Centro province	2011	Students, 14–19	Urine, amplification test	536	1.1	Urine, amplification test	536	0.0	NR	NR	NR
South-East Asia Region
Jatapai et al., 2013¹⁴⁸	Thailand, national	Nov 2008–May 2009	Military recruits, 17–29	Urine, amplification test	2123	7.9	Urine, amplification test	2123	0.9	NR	NR	NR
European Region
Sviben et al., 2015¹⁴⁹	Croatia, Zagreb	Pre-2014	Controls in case-control study, 18–66	NR	NR	NR	NR	NR	NR	Urine, amplification test	200	2.0
Ikonomidis et al., 2015⁹⁸	Greece, Thessaly State	Feb 2012–Nov 2015	Attendees at urology and gynaecology clinic, adult	Genital, amplification test	171	0.6	NR	NR	NR	NR	NR	NR
Matteelli et al., 2016¹⁰⁵	Italy, Brescia	Nov 2012–Mar 2013	Sexually active students, > 18	Urine, amplification test	762	1.4	Urine, amplification test	762	0.0	NR	NR	NR
Gravningen et al., 2013¹⁰⁸	Norway, Finnmark	2009	Sexually active youth, 15–20	Urine, amplification test	505	3.4	NR	NR	NR	NR	NR	NR
Babinská et al., 2017¹¹⁰	Slovakia, eastern parts	2011	Community members, adult	Urine, amplification test	344	2.0	NR	NR	NR	NR	NR	NR
Fernández-Benítez et al., 2013¹¹¹	Spain, Laviana and Asturias	Nov 2010–Dec 2011	Sexually active youth, 15–24	Urine, amplification test	210	4.3	NR	NR	NR	NR	NR	NR
Field et al., 2018¹¹³	United Kingdom, national	Sep 2010–Aug 2012	Sexually active adults, 16–44	NR	NR	NR	NR	NR	NR	Urine, amplification test	1827	0.0
Sonnenberg et al., 2013¹¹⁴	United Kingdom, national	Sep 2010–Aug 2012	Sexually active adults, 16–44	Urine, amplification test	1885	1.9	Urine, amplification test	1885	0.1	NR	NR	NR
Eastern Mediterranean Region
Arbabi et al., 2014¹²²	Iran (Islamic Republic of), Kashan	Oct 2012–Aug 2013	Attendees at a public health unit, 16–60	NR	NR	NR	NR	NR	NR	Genital fluid, culture	233	0.9
Yeganeh et al., 2013¹⁵⁰	Iran (Islamic Republic of), Tehran	Pre-2013	Urology clinic attendees, 18–50	Urine, amplification test	100	4.0	NR	NR	NR	NR	NR	NR
Western Pacific Region
Corsenac et al., 2015¹³⁷	New Caledonia, national	Aug–Dec 2012	Attendees at a primary health-care clinic, 18–49	Urine, amplification test	232	7.8	Urine, amplification test	232	3.4	NR	NR	NR
Choe et al., 2012¹⁴³	Republic of Korea, Seoul	Mar–Dec 2010	Attendees at a health examination clinic, 20–59	Urine, amplification test	807	7.9	Urine, amplification test	807	0.6	NR	NR	NR
Kim et al., 2011¹⁴⁴	Republic of Korea, Uijeongbu	Jul–Dec 2010	Attendees at a check-up clinic, 20–60	Urine, amplification test	430	6.7	Urine, amplification test	430	0.5	Urine, amplification test	430	0.2

HIV: human immunodeficiency virus; NR: not reported; WHO: World Health Organization.

^a Tests were either nucleic acid amplification test or culture.